The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients
The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients
复制标题
ATP7B 基因多态性可预测肺癌患者铂类化疗的临床结果。
DOI：
10.1007/s13277-014-2072-0
复制
发表时间：
2014-08-01
期刊：
影响因子：
--
通讯作者：
Liu, Zhao-Qian
中科院分区：
文献类型：
--
作者：
Li, Xiang-Ping;Yin, Ji-Ye;Liu, Zhao-Qian
本研究旨在探讨ATP7B基因多态性对中国汉族肺癌患者铂基化疗的影响。本研究共纳入338例中国汉族肺癌患者。所有患者都接受了至少两个周期的铂类化疗。选择ATP7B的四个标签snp （rs1061472、rs9535826、rs7999812和rs9535828）来评估它们对这些患者铂基化疗的影响。发现ATP7B rs9535828和rs9535826与中国汉族肺癌患者铂耐药相关。携带ATP7B rs9535828等位基因的患者对铂类药物的易感性增加（OR 1.96, 95% CI 1.17-3.30, p < 0.01）。携带ATP7B rs9535826基因G等位基因的患者对铂类药物的敏感性最高（OR 2.05, 95% CI 1.19 ~ 3.52, p < 0.01）。提示ATP7B基因多态性可影响铂类化疗的疗效，ATP7B基因可作为评价中国汉族肺癌患者铂类化疗疗效的预测指标。
This study aims to investigate the influence of ATP7B genetic polymorphism to platinum-based chemotherapy in Chinese Han lung cancer patients. A total of 338 Chinese Han lung cancer patients were enrolled in this study. All patients underwent at least two cycles of platinum-based chemotherapy. Four tag SNPs of ATP7B (rs1061472, rs9535826, rs7999812, and rs9535828) were selected to evaluate their impacts to platinum-based chemotherapy in these patients. ATP7B rs9535828 and rs9535826 were found to be associated with platinum resistance in Chinese Han lung cancer patients. Patients with A allele in ATP7B rs9535828 presented an increased susceptibility to platinum drugs (OR 1.96, 95 % CI 1.17-3.30, p < 0.01). Patients with G allele in ATP7B rs9535826 had the highest susceptibility to platinum drugs (OR 2.05, 95 % CI 1.19-3.52, p < 0.01). Our findings suggest that ATP7B genetic polymorphisms could affect the therapeutic efficacy of platinum-based chemotherapy, and ATP7B gene might be considered as predictive markers for the efficacy evaluation of platinum-based chemotherapy in Chinese Han lung cancer patients.